ClinicalTrials.gg
CompletedNCT05301517Updated Jun 6, 2023

A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies

A Phase 3 interventional study of SEPO® and Roxadustat in Chemotherapy Induced Anemia, sponsored by FibroGen. Completed at 45 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-06.

Sponsored by FibroGen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
159
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing roxadustat in Anemia — 2 open to participants now, 4 under way, 3 of them phase 3. roxadustat · Anemia.

Enrollment
20th of 43
159 · median 154
Started
2022
with 1 other
Phase 3
25 of 43
1 open now
Registered
35th of 43
by date
Lead sponsor
20 of 43
FibroGen

Among the 43 studies testing roxadustat in Anemia, this one is the 20th largest by enrollment, is one of 2 that started in 2022, is one of 25 in phase 3, and was the 35th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

2 of the 43 studies testing roxadustat in Anemia are open now. Recruiting first, the newest first:

All 2 open studies →

About roxadustat

roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing roxadustat in Anemia, or all of them as a file.
02

Study summary

The main goal of this study is to evaluate the efficacy of roxadustat for treatment of anemia in participants with non-myeloid malignancies receiving multi-cycle treatments of myelosuppressive chemotherapy.

Read the detailed description

Participants who are eligible for participation will be randomized to roxadustat and SEPO® (recombinant human erythropoietin-α [rHuEPO-α]), and undergo a 12-week treatment period followed by a 4-week follow-up period.

03

Conditions studied

  • Chemotherapy Induced Anemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of non-myeloid , by histological or cytological confirmation.
  • Anemia related to myelosuppressive chemotherapy, defined as ≤100 g/L at screening with documented participant's Hb level decrease ≥10 g/L after the initiation of chemotherapy as judged by the investigator.
  • Planned concurrent treatment of cancer (myelosuppressive chemotherapy) for at least 8 additional weeks.
  • Body weight ≥40 kg.
  • (ECOG) performance status of 1 or 2.
  • Ferritin ≥50 nanograms (ng)/milliliter (mL) and transferrin saturation (TSAT) ≥10%.

Key Exclusion Criteria:

  • Participants with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure.
  • Participants who are only receiving hormonal products, biological products, novel products (such as programmed cell death protein-1 [] and programmed death-ligand 1 [PD-L1] checkpoint inhibitors) or targeted biological or radiation therapy to treat/manage their cancer, however if chemotherapy is co-administered with these products, then it is acceptable to enroll the participant.
  • Participants with hematocrit (HCT) ≥36%.
  • Participants who have received an RBC transfusion or ESA within 4 weeks of randomization.
  • Thromboembolic event (including but not limited to deep vein thrombosis [DVT], pulmonary embolism, myocardial infarction, stroke, [TIA] within previous 6 months of screening.
  • anemia due to other etiologies such as iron deficiency, vitamin B12 or folate deficiency, anemia, hemolysis, hemorrhage, or hereditary anemia such as sickle cell anemia or thalassemia.
  • The Investigator judges that the participant will be unable to fully participate in the study and complete it for any reason, including inability to comply with study procedures and treatment, addiction, or any other relevant medical conditions.

Note: Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
159 participants (actual)

Study arms

  • Experimental
    Roxadustat

    Participants will receive roxadustat, administered orally 3 times per week (TIW) for 12 weeks to achieve Hb levels of 100-120 g/L. The starting dose will be based on the participant's weight group. The maximum dose for individual participants may not exceed 3.5 milligrams (mg)/kilogram (kg) or 400 mg TIW whichever is lower.

    Drug: Roxadustat

  • Active comparator
    SEPO®

    Participants will receive SEPO®, injected subcutaneously TIW for 12 weeks to achieve Hb levels of 100-120 g/L. The starting dose will be 150 international units (IU)/kg subcutaneously TIW.

    Drug: SEPO®

Interventions

  • DrugSEPO®

    SEPO® will be administered per dose and schedule specified in the arm description.

    Also known as: Recombinant human erythropoietin-α [rHuEPO-α]

  • Roxadustat will be administered per dose and schedule specified in the arm description.

    Also known as: FG-4592

06

What researchers measure

Primary outcomes

  1. Change in Hemoglobin (Hb) Level From Baseline to the Level Averaged Over Weeks 9-13

    Hb levels measured from Weeks 9 through 13 will be averaged in order to provide a single measure for comparison to the baseline Hb levels.

    Time frame: Baseline, Weeks 9 through 13

Secondary outcomes

  1. Percentage of Participants who Achieve a ≥10 Grams (g)/Liter (L) Increase in Hb From Baseline Through Week 13

    Time frame: Baseline through Week 13

  2. Percentage of Participants who Require Red Blood Cell (RBC) Transfusion or Hb <60 g/L or with any Hb< 60 g/L From Week 5 Through Week 13

    Time frame: Week 5 through Week 13

  3. Change From Baseline in Functional Assessment of Cancer Therapy-Anemia (FACT-An) Subscale Score Averaged Over Weeks 9-13

    FACT-An subscale scores will be averaged over Weeks 9 through 13 in order to provide a single measure for comparison to the baseline score.

    Time frame: Baseline, Weeks 9 through 13

  4. Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Subscale Score Averaged Over Weeks 9-13

    FACIT-F subscale scores will be averaged over Weeks 9 through 13 in order to provide a single measure for comparison to the baseline score.

    Time frame: Baseline, Weeks 9 through 13

  5. Percentage of Participants who Require Dose Reduction or a Dose-Hold of Chemotherapy Due to Anemia

    Time frame: Baseline through Week 13

  6. Change in Hb From Baseline up to 4 Weeks After the Last Dose of Chemotherapy During the Treatment Period

    Time frame: Baseline up to 4 weeks after the last dose of chemotherapy (up to Week 16)

  7. Change in Hb From Baseline Through Week 9

    Time frame: Baseline through Week 9

  8. Change in Hb From Baseline Through Week 13

    Time frame: Baseline through Week 13

  9. Percentage of Participants who Achieve a ≥ 15 g/L Increase in Hb From Baseline Through Week 13

    Time frame: Baseline through Week 13

  10. Percentage of Participants who Achieve Hb Levels ≥ 110 g/L From Baseline Through Week 13

    Time frame: Baseline through Week 13

  11. Percentage of Participants who Achieve an Increase in Hb of 15 g/L or Attaining a Hb of 110 g/L From Baseline Through Week 13

    Time frame: Baseline through Week 13

  12. Time to First RBC Transfusion

    Time frame: Baseline up to Week 13

  13. Percentage of Participants Requiring 1 or More RBC Transfusion

    Time frame: Baseline up to Week 13

  14. Number of RBC Transfusions Adjusted for Exposure From Baseline Through Week 13

    Time frame: Baseline through Week 13

  15. Percentage of Participants who Require RBC Transfusion as Medical Intervention and/or Erythropoiesis-Stimulating Agent (ESA) as a Rescue Agent

    Time frame: Baseline through Week 13

07

Study locations

45 sites
  • Affiliated Hospital of Hebei University
    Baoding, China
  • Cancer Hospital, Chinese Academy of Medical Sciences
    Beijing, China
  • Capital Medical University Chest Hospital
    Beijing, China
  • Peking University Cancer Hospital
    Beijing, China
  • Jilin Cancer Hospital
    Changchun, China
  • Hunan Cancer Hospital
    Changsha, China
  • Sichuan Cancer Hospital
    Chengdu, China
  • Chongqing Bishan People's Hospital
    Chongqing, China
  • The Second Affiliated Hospital of Third Military Medical University (Xinqiao Hospital)
    Chongqing, China
  • Deyang People's Hospital
    Deyang, China
  • The First People's Hospital of Foshan
    Foshan, China
  • Fujian Medical University Union Hospital
    Fuzhou, China
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University - Gynecologic Oncology Department
    Guangzhou, China
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University - Oncology Department
    Guangzhou, China
  • Hangzhou Cancer Hospital
    Hangzhou, China
  • Zhejiang Cancer Hospital
    Hangzhou, China
  • Harbin Medical University Cancer Hospital
    Harbin, China
  • Anhui Cancer Hospital
    Hefei, China
  • Jiangxi Cancer Hospital
    Jiangxi, China
  • Shandong First Medical University Cancer Hospital
    Jinan, China
  • The Second Hospital of Lanzhou University
    Lanzhou, China
  • Jiangsu Province Hospital
    Nanjing, China
  • The People's Hospital of Guangxi Zhuang Autonomous Region
    Nanning, China
  • Neijiang Second People's Hospital
    Neijiang, China
  • Ningbo First Hospital
    Ningbo, China
  • Jiangxi Pingxiang People's Hospital
    Pingxiang, China
  • The Affiliated Hospital of Qingdao University
    Qingdao, China
  • Fudan University Shanghai Cancer Center
    Shanghai, China
  • Shanghai Chest Hospital
    Shanghai, China
  • Shanghai Fifth People's Hospital
    Shanghai, China
  • Liaoning Cancer Hospital & Institute
    Shenyang, China
  • The First Hospital of China Medical University - Oncology Department Breast Cancer Group
    Shenyang, China
  • The First Hospital of China Medical University - Oncology Department Lung Cancer Group
    Shenyang, China
  • Peking University Shenzhen Hospital
    Shenzhen, China
  • Shanxi Cancer Hospital
    Taiyuan, China
  • Union Hospital Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, China
  • University of Science and Technology
    Wuhan, China
  • Wuhan Fourth Hospital
    Wuhan, China
  • The Second Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, China
  • Cancer Hospital of Xinjiang Medical University
    Xinjiang, China
  • Xuzhou Central Hospital
    Xuzhou, China
  • Yantai Yuhuangding Hospital
    Yantai, China
  • General Hospital of Ningxia Medical University
    Yinchuan, China
  • Henan Cancer Hospital
    Zhengzhou, China
  • Zhuzhou Central Hospital
    Zhuzhou, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Apr 2023, 12 months.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 12 months is below that.

Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2022
First posted
Mar 29, 2022
StartActual
Mar 16, 2022
Primary completionActual
Apr 3, 2023
CompletionActual
Apr 21, 2023
Last update
Jun 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05301517
Lead sponsor
FibroGen
Responsible party
Sponsor
First posted
Mar 29, 2022
Start date
Mar 16, 2022
Primary completion
Apr 3, 2023
Completion
Apr 21, 2023
Last update
Jun 6, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roxadustat

Start the discussion